糖胃康对糖尿病胃轻瘫大鼠胃窦SCF-Kit信号途径影响的研究
|
摘要
目的
在系统整理研究古代文献的基础上,结合现今消渴及其并发症的发病特点,对消渴胃病(糖尿病胃轻瘫)的理法方药进行理论探讨,丰富中医学对消渴胃病的认识；探讨糖尿病胃轻瘫大鼠胃窦SCF-Kit信号途径在Cajal间质细胞受损中的作用,进一步阐明中药糖胃康治疗糖尿病胃轻瘫的作用部位、环节及分子机制,为临床开发防治糖尿病胃轻瘫的有效中药制剂奠定基础。
方法
理论研究：对消渴胃病的历史源流、病机特点及防治方法等进行分析研究,讨论糖胃康的组方原则及药效分析。
实验研究：采用链脲佐菌素及高糖高脂饲料不规则喂养(即单日上午进食,双日下午进食)诱导糖尿病胃轻瘫大鼠模型,随机分为7组(正常对照组、糖尿病模型组、糖尿病胃轻瘫模型组、糖胃康高剂量组、糖胃康中剂量组、糖胃康低剂量组和西沙比利治疗组)进行实验研究。观察糖胃康对糖尿病胃轻瘫模型组大鼠糖、脂代谢及胰岛β细胞功能的影响；通过透射电镜观察各组大鼠胃窦组织ICC超微结构的变化；采用Western blot检测各组大鼠胃窦平滑肌组织c-kit蛋白、SCF蛋白表达水平,RT-PCR测定各组大鼠胃窦平滑肌组织SCF mRNA的表达。
结果
1.消渴胃病具有“本虚标实”的病机特点,且“本虚之中,脾虚为要”、“标实之中,毒邪为甚”,糖胃康针对此病机而设,具有健脾和胃,理气排毒之功效。
2.糖尿病及糖尿病胃轻瘫造模研究中：在造模后前4周糖尿病模型组及糖尿病胃轻瘫模型组大鼠与正常对照组大鼠相比较,日进食量均明显增加,有显著性差异(P<0.05或P<0.01),且以糖尿病模型组尤为明显；糖尿病胃轻瘫模型组大鼠第6周后,日进食量减少,第8周与正常对照组相比较,有统计学意义(P<0.01)；与糖尿病模型组相比较,第4周后,糖尿病胃轻瘫模型组大鼠日进食量减少,有显著性差异(P<0.01)。造模后前2周,糖尿病模型组和糖尿病胃轻瘫模型组大鼠日饮水量均显著增加,与正常对照组比较,有显著性差异(P<0.01)；造模4周后,糖尿病胃轻瘫模型组大鼠日饮水量较糖尿病模型组减少,第6周后尤为明显,有统计学意义(P<0.05或P<0.01)。糖尿病模型组和糖尿病胃轻瘫模型组大鼠体重随着时间的延长(造模2周后)均呈现体重下降的趋势,与正常对照组相比较,有显著性差异(P<0.05或P<0.01),且以糖尿病胃轻瘫组大鼠下降尤为明显；与糖尿病模型组相比较,糖尿病胃轻瘫模型组大鼠体重下降有统计学意义(P<0.05或P<0.01)。同时,造模后糖尿病模型组及糖尿病胃轻瘫模型组大鼠均出现大便量少、色淡、质稀软、互相粘连、不成形等大便性状的改变,且以糖尿病胃轻瘫模型组大鼠尤为明显。在胃排空功能的测定方面,糖尿病模型组和糖尿病胃轻瘫模型组大鼠胃排空功能均有所下降,与正常对照组相比较,糖尿病模型组大鼠胃排空下降无统计学意义(P>0.05),而糖尿病胃轻瘫模型组大鼠有显著性差异(P<0.01)。
3.糖胃康对糖尿病胃轻瘫模型大鼠糖脂代谢和胰岛β细胞功能影响的研究中：糖胃康高、中剂量组分别与糖尿病胃轻瘫模型组相比较,大鼠空腹血糖及胰岛素水平均明显下降(P<0.01),胰岛素敏感指数均升高(P<0.01)、抵抗指数均降低(P<0.01)；胰岛形状较规则,细胞数量增多,胞浆较丰富；胰岛β细胞团平均面积均明显增大(P<0.05)；且胃排空功能与西沙比利治疗组相比较无明显差异。说明高、中剂量的糖胃康可通过其有效的降糖作用来改善IR,又可以通过其改善IR的作用,增加胰岛素敏感性,恢复胰岛β细胞的分泌功能,缓解糖尿病胃轻瘫的临床症状。模型组(糖尿病模型组和糖尿病胃轻瘫模型组)大鼠胰岛内有明显的脂质沉积,可能是糖尿病及糖尿病胃轻瘫形成的重要病理因素。实验后期,模型组大鼠体重出现了明显的下降,且以糖尿病胃轻瘫模型组为甚,分析原因可能为血糖较高,细胞供能不足,机体分解脂肪供能而导致的消瘦,与临床上未经控制的血糖,糖尿病病程进展而出现“消瘦”的临床特征相符合；糖尿病胃轻瘫模型组大鼠因饮食减少,供能更为不足而致体重下降更加明显。药物干预后,糖胃康高、中剂量组大鼠体重均明显增加,内脏脂肪/体重均明显降低,说明其对血脂具有调节作用,能够延缓糖尿病病程进展。
4.糖胃康对糖尿病胃轻瘫模型大鼠Cajal间质细胞的影响研究中：电镜观察结果显示,糖尿病胃轻瘫模型组大鼠胃窦ICC与其它的ICC之间、平滑肌细胞之间以及神经末梢之间的缝隙连接明显减少,尚存细胞间的连接结构不清,间隙增大。部分ICC的基膜与细胞膜分离,形成空洞；线粒体肿胀、空泡样变、甚至溶解；胞质广泛溶解,有大量的胞质内空泡形成；细胞器数量减少明显。药物干预后,糖胃康高、中剂量组大鼠胃窦ICC与其它的ICC之间、平滑肌细胞之间以及神经末梢之间的缝隙连接均明显增多,ICC的基膜结构趋于完整,部分线粒体轻度肿胀,细胞器数量较正常对照组无明显差异。Western blot检测显示：糖尿病胃轻瘫模型组大鼠胃窦平滑肌组织c-kit蛋白表达水平显著降低,与正常对照组相比,具有显著性差异(P<0.01)；药物干预后,糖胃康高、中剂量组大鼠胃窦平滑肌组织c-kit蛋白表达水平较糖尿病胃轻瘫模型组均显著升高(P<0.01),且与正常对照组比较差异均无统计学意义(P>0.05)。
5.糖胃康对糖尿病胃轻瘫模型大鼠SCF蛋白和基因表达的影响研究中：糖尿病胃轻瘫模型组大鼠胃窦平滑肌组织SCF的m RNA及蛋白质相对表达水平均显著降低,与正常对照组相比,具有显著性差异(P<0.01)；药物干预后,糖胃康高、中剂量组大鼠胃窦平滑肌组织SCF的m RNA及蛋白质相对表达水平较糖尿病胃轻瘫模型组均显著升高,差异有统计学意义(P<0.05或P<0.01),且与正常对照组比较差异无统计学意义(P>0.05)。
结论
1.脾虚失运是消渴病形成的关键环节,热毒、湿毒、瘀毒、浊毒等毒邪既是消渴病的病理产物,又是消渴胃病形成的重要致病因素。消渴胃病具有“本虚标实”的病机特点,且“本虚之中,脾虚为要”、“标实之中,毒邪为甚”,治疗原则上应病证结合、标本兼顾。针对消渴胃病“脾虚毒盛”的主要病机,结合中医药理论及现代药理研究,精心组方而成的糖胃康具有健脾和胃,理气排毒的功效。
2.在单次腹腔注射STZ的基础上,采用高糖高脂饲料不规则喂养(即单日上午进食,双日下午进食)的方法能成功复制糖尿病胃轻瘫模型。
3.糖胃康对糖尿病胃轻瘫模型大鼠糖、脂代谢紊乱具有明显的改善作用,在一定程度上能改善IR,恢复胰岛β细胞的功能,增强DGP的胃排空功能,且呈一定的量效关系。糖胃康可通过改善糖尿病胃轻瘫模型大鼠糖、脂代谢紊乱,上调SCF表达水平,调控ICC的分化、发育和表型维持,恢复SCF/Kit的信号传递系统通路,从而使胃平滑肌收缩功能改变,增强DGP的胃排空功能。
Objective
On the basis of ancient literature, combined with today's clinical peculiarity of diabetes and complications of diabetes,probe into diabetes gastroparesis treatment for theoretical approach, and enrich Chinese medicine on diabetes stomach; Study the role of diabetes gastroparesis (DGP) rats gastric antral SCF-Kit pathway in the damage of interstitial cells of cajal (ICC) and the mechanism of TangWeiKang in order to lay the foundation to develop an effective medicine to control DGP.
Methods
Theoretical studies:Research the origin, the pathogenesis and treatment methods of gastric disease of diabetes, and discuss TangWeikang's prescription principles and efficacy analysis.
Experimental studies:At first,we have used Streptozotocin by cavitas abdominalis injection and high sugar high fat diet to irregularly feed (morning meal in odd-number days, afternoon eating in even-number days) rats to induce DGP model, and have divided rats into 7 Groups (normal comparison group, diabetes model group, diabetes gastroparesis model group,TangWeiKang high dose group, TangWeiKang medium dose group, TangWeiKang low dose group and XiShaBiLi treatment group) for experimental research. Then we have observed TangWeiKang'influence on improving carbohydrate and lipid metabolism and pancreaticβcell function of DGP model group rats; and observed each group of rats gastric antrum ICC ultrastructure through transmission electron microscopy; and taken the Western blot to detect gastric tissue c-kit and SCF protein expression level, and taken RT-PCR to determinate the expression of gastric tissue SCF mRNA.
Results
.1.Gastric disease of diabetes has a pathogenesis characteristic that Ben is deficient and Biao is excess. Furthermore, the spleen's deficiency is the most important,and the toxic'exuberance is the most obvious. Aiming at these, we have established a prescription TangWeiKang that can make the spleen-stomach healthy and smooth Qi and eliminate toxins.
2. In the research of making DM model and DGP model:Former 4 weeks after the model, quantities of food-intake of DM model group and DGP model group rats have obviously increased, compared with normal comparison group, and differences are significant (P<0.05 or P<0.01).Moreover, DM model group is more obvious. After 6 weeks, quantities of food-intake of DGP model group rats have decreased, compared with normal comparison group, and differences are significant in 8thweek(P<0.01). Former 2 weeks after the model, quantities of hydroposia of DM model group and DGP model group rats have obviously increased, compared with normal comparison group, and differences are significant (P<0.01). After 4 weeks, quantities of hydroposia of DGP model group rats have decreased more than that of DM model group.Besides, differences are more significant after 6 weeks, and are significant (P<0.05 or P<0.01). As an extension of time, the weights of DM model group and DGP model group rats have obviously reduced, compared with normal comparison group, and differences are signif icant(P<0.05 or P<0.01). Moreover, DGP model group is more obvious. and differences are significant (P<0.05 or P<0.01), compared with DM model group. At the same time, the stool of DM model group and DGP model group rats has appeared some changes, such as less, pale, softer, mutual adhesion, irregular shape and so on. Moreover, DGP model group is more obvious. The function of gastric emptying of DM model group and DGP model group rats has decreased, and the decline of gastric emptying of DM model group rats is non-obvious(P>0.05), compared with normal comparison group,but that of DGP model group rats is significant (P<0.01).
3. TangWeiKang' influence on improving carbohydrate and lipid metabolism and pancreaticβcell function of DGP model group rats: Fasting plasma glucose and fasting serum insulin and Homa-IR of TangWeiKang high dose group and medium dose group rats have obviously descended,but insulin sensitivity index of TangWeiKang high dose group and medium dose group rats have went up. Islet cell shape of TangWeiKang high dose group and medium dose group rats is more regular, and quantity of cell is more,and endochylema is more rich, compared with DGP model group rats. But the function of gastric emptying of TangWeiKang high dose group and medium dose group rats has no obvious difference with XiShaBiLi treatment group rats. These have explained TangWeiKang high dose and medium dose can improve IR by means of reducing glucose, and raise insulin sensibility,and renew pancreaticβcell function, and relieve clinical symptoms. There are obvious lipid accumulation in langerhans'islet in the DM model group and DGP model group rats, which can be important pathology factors that come into being DM and DGP. The weights of model group (DM model group and DGP model group)rats have dropped obviously in the experiment later stage, and DGP model group is most obvious. The reason can be high plasma glucose that lead to fat to resolve. The weights of TangWeiKang high dose group and medium dose group rats have obviously increased after invasion, and the ratio of fat in viscera and weight has obviously decreased,which have illustrated TangWeiKang can adjust lipid and put off the progress of DM.
4. TangWeiKang' influence on ICC of DGP model group rats:The gap joints between gastric antral ICC and smooth muscle and nerve endings have markedly decreased in the DGP model group rats through transmission electron microscopy, and the structures of intercellular connections are vague,and the gap has magnified. A part of ICC' basement layer has been separated with cytomembrane, which has formed cavity.we can also find mitochondria swelling, vacuolar degeneration,even dissolution, and cytoplasm resolving, and the quantity of cell organ has decreased. The gap joints between gastric antral ICC and smooth muscle and nerve endings are markedly more in the TangWeiKang high dose group and medium dose group than DGP model group after invasion, with more developed slide endoplasmic reticulum, Golgi apparatus and mitochondria. We have found the expression levels of c-kit protein of DGP model group have obviously decreased by western blot analysis method, compared with normal comparison group, and differences are significant (P<0.01). The expression levels of c-kit protein in the TangWeiKang high dose group and medium dose group are obviously higher than DGP model group after invasion (P<0.01), but the differences are non-obvious (P>0.05), compared with normal comparison group.
5. TangWeiKang'influence on SCF protein and gene expression of DGP model group rats:We have found the expression levels of SCF protein and gene expression of DGP model group have obviously decreased, compared with normal comparison group, and differences are significant (P<0.01). The expression levels of SCF protein and gene expression in the TangWeiKang high dose group and medium dose group are obviously higher than DGP model group after invasion (P<0.05 or P<0.01), but the differences are non-obvious (P>0.05), compared with normal comparison group.
Conclusion
1. Spleen-deficiency and losing in the transformation and transportation is a key link during diabetes mellitus formation. Toxins, such as toxic heat, damp toxin, ecchymosis toxin, turbid toxin and so on, are not only pathological products of diabetes mellitus,but also important pathogenic factors during gastric disease of diabetes formation. Gastric disease of diabetes have a pathogenesis characteristic that Ben is deficient and Biao is excess. Furthermore, the spleen's deficiency is the most importance, and the toxic'exuberance is the most obvious. Treatment principle should combine Bing with Zheng,and treat Biao and Ben at the same time. Aiming at these, we have established a prescription TangWeiKang that can make the spleen-stomach healthy and smooth Qi and eliminate toxins.
2. On the basis of single intraperitoneal injection STZ, we have fed model group rats on high sugar and high fat diet irregularly (morning meal in odd-number days, afternoon eating in even-number days).we have successfully copied diabetic gastroparesis model in this way.
3.TangWeiKang have a positive influence on improving carbohydrate and lipid metabolism and pancreaticβcell function, to a certain extent, can improve the IR, restore pancreatic isletβcell functions, enhance gastric emptying of DGP, and these are at the dose-effect relationship. TangWeiKang may rebuild the SCF-Kit pathway for ICC phenotype reversion by upregulating the level of SCF, so as to maintain normal gastrointestinal motor function.
在系统整理研究古代文献的基础上,结合现今消渴及其并发症的发病特点,对消渴胃病(糖尿病胃轻瘫)的理法方药进行理论探讨,丰富中医学对消渴胃病的认识；探讨糖尿病胃轻瘫大鼠胃窦SCF-Kit信号途径在Cajal间质细胞受损中的作用,进一步阐明中药糖胃康治疗糖尿病胃轻瘫的作用部位、环节及分子机制,为临床开发防治糖尿病胃轻瘫的有效中药制剂奠定基础。
方法
理论研究：对消渴胃病的历史源流、病机特点及防治方法等进行分析研究,讨论糖胃康的组方原则及药效分析。
实验研究：采用链脲佐菌素及高糖高脂饲料不规则喂养(即单日上午进食,双日下午进食)诱导糖尿病胃轻瘫大鼠模型,随机分为7组(正常对照组、糖尿病模型组、糖尿病胃轻瘫模型组、糖胃康高剂量组、糖胃康中剂量组、糖胃康低剂量组和西沙比利治疗组)进行实验研究。观察糖胃康对糖尿病胃轻瘫模型组大鼠糖、脂代谢及胰岛β细胞功能的影响；通过透射电镜观察各组大鼠胃窦组织ICC超微结构的变化；采用Western blot检测各组大鼠胃窦平滑肌组织c-kit蛋白、SCF蛋白表达水平,RT-PCR测定各组大鼠胃窦平滑肌组织SCF mRNA的表达。
结果
1.消渴胃病具有“本虚标实”的病机特点,且“本虚之中,脾虚为要”、“标实之中,毒邪为甚”,糖胃康针对此病机而设,具有健脾和胃,理气排毒之功效。
2.糖尿病及糖尿病胃轻瘫造模研究中：在造模后前4周糖尿病模型组及糖尿病胃轻瘫模型组大鼠与正常对照组大鼠相比较,日进食量均明显增加,有显著性差异(P<0.05或P<0.01),且以糖尿病模型组尤为明显；糖尿病胃轻瘫模型组大鼠第6周后,日进食量减少,第8周与正常对照组相比较,有统计学意义(P<0.01)；与糖尿病模型组相比较,第4周后,糖尿病胃轻瘫模型组大鼠日进食量减少,有显著性差异(P<0.01)。造模后前2周,糖尿病模型组和糖尿病胃轻瘫模型组大鼠日饮水量均显著增加,与正常对照组比较,有显著性差异(P<0.01)；造模4周后,糖尿病胃轻瘫模型组大鼠日饮水量较糖尿病模型组减少,第6周后尤为明显,有统计学意义(P<0.05或P<0.01)。糖尿病模型组和糖尿病胃轻瘫模型组大鼠体重随着时间的延长(造模2周后)均呈现体重下降的趋势,与正常对照组相比较,有显著性差异(P<0.05或P<0.01),且以糖尿病胃轻瘫组大鼠下降尤为明显；与糖尿病模型组相比较,糖尿病胃轻瘫模型组大鼠体重下降有统计学意义(P<0.05或P<0.01)。同时,造模后糖尿病模型组及糖尿病胃轻瘫模型组大鼠均出现大便量少、色淡、质稀软、互相粘连、不成形等大便性状的改变,且以糖尿病胃轻瘫模型组大鼠尤为明显。在胃排空功能的测定方面,糖尿病模型组和糖尿病胃轻瘫模型组大鼠胃排空功能均有所下降,与正常对照组相比较,糖尿病模型组大鼠胃排空下降无统计学意义(P>0.05),而糖尿病胃轻瘫模型组大鼠有显著性差异(P<0.01)。
3.糖胃康对糖尿病胃轻瘫模型大鼠糖脂代谢和胰岛β细胞功能影响的研究中：糖胃康高、中剂量组分别与糖尿病胃轻瘫模型组相比较,大鼠空腹血糖及胰岛素水平均明显下降(P<0.01),胰岛素敏感指数均升高(P<0.01)、抵抗指数均降低(P<0.01)；胰岛形状较规则,细胞数量增多,胞浆较丰富；胰岛β细胞团平均面积均明显增大(P<0.05)；且胃排空功能与西沙比利治疗组相比较无明显差异。说明高、中剂量的糖胃康可通过其有效的降糖作用来改善IR,又可以通过其改善IR的作用,增加胰岛素敏感性,恢复胰岛β细胞的分泌功能,缓解糖尿病胃轻瘫的临床症状。模型组(糖尿病模型组和糖尿病胃轻瘫模型组)大鼠胰岛内有明显的脂质沉积,可能是糖尿病及糖尿病胃轻瘫形成的重要病理因素。实验后期,模型组大鼠体重出现了明显的下降,且以糖尿病胃轻瘫模型组为甚,分析原因可能为血糖较高,细胞供能不足,机体分解脂肪供能而导致的消瘦,与临床上未经控制的血糖,糖尿病病程进展而出现“消瘦”的临床特征相符合；糖尿病胃轻瘫模型组大鼠因饮食减少,供能更为不足而致体重下降更加明显。药物干预后,糖胃康高、中剂量组大鼠体重均明显增加,内脏脂肪/体重均明显降低,说明其对血脂具有调节作用,能够延缓糖尿病病程进展。
4.糖胃康对糖尿病胃轻瘫模型大鼠Cajal间质细胞的影响研究中：电镜观察结果显示,糖尿病胃轻瘫模型组大鼠胃窦ICC与其它的ICC之间、平滑肌细胞之间以及神经末梢之间的缝隙连接明显减少,尚存细胞间的连接结构不清,间隙增大。部分ICC的基膜与细胞膜分离,形成空洞；线粒体肿胀、空泡样变、甚至溶解；胞质广泛溶解,有大量的胞质内空泡形成；细胞器数量减少明显。药物干预后,糖胃康高、中剂量组大鼠胃窦ICC与其它的ICC之间、平滑肌细胞之间以及神经末梢之间的缝隙连接均明显增多,ICC的基膜结构趋于完整,部分线粒体轻度肿胀,细胞器数量较正常对照组无明显差异。Western blot检测显示：糖尿病胃轻瘫模型组大鼠胃窦平滑肌组织c-kit蛋白表达水平显著降低,与正常对照组相比,具有显著性差异(P<0.01)；药物干预后,糖胃康高、中剂量组大鼠胃窦平滑肌组织c-kit蛋白表达水平较糖尿病胃轻瘫模型组均显著升高(P<0.01),且与正常对照组比较差异均无统计学意义(P>0.05)。
5.糖胃康对糖尿病胃轻瘫模型大鼠SCF蛋白和基因表达的影响研究中：糖尿病胃轻瘫模型组大鼠胃窦平滑肌组织SCF的m RNA及蛋白质相对表达水平均显著降低,与正常对照组相比,具有显著性差异(P<0.01)；药物干预后,糖胃康高、中剂量组大鼠胃窦平滑肌组织SCF的m RNA及蛋白质相对表达水平较糖尿病胃轻瘫模型组均显著升高,差异有统计学意义(P<0.05或P<0.01),且与正常对照组比较差异无统计学意义(P>0.05)。
结论
1.脾虚失运是消渴病形成的关键环节,热毒、湿毒、瘀毒、浊毒等毒邪既是消渴病的病理产物,又是消渴胃病形成的重要致病因素。消渴胃病具有“本虚标实”的病机特点,且“本虚之中,脾虚为要”、“标实之中,毒邪为甚”,治疗原则上应病证结合、标本兼顾。针对消渴胃病“脾虚毒盛”的主要病机,结合中医药理论及现代药理研究,精心组方而成的糖胃康具有健脾和胃,理气排毒的功效。
2.在单次腹腔注射STZ的基础上,采用高糖高脂饲料不规则喂养(即单日上午进食,双日下午进食)的方法能成功复制糖尿病胃轻瘫模型。
3.糖胃康对糖尿病胃轻瘫模型大鼠糖、脂代谢紊乱具有明显的改善作用,在一定程度上能改善IR,恢复胰岛β细胞的功能,增强DGP的胃排空功能,且呈一定的量效关系。糖胃康可通过改善糖尿病胃轻瘫模型大鼠糖、脂代谢紊乱,上调SCF表达水平,调控ICC的分化、发育和表型维持,恢复SCF/Kit的信号传递系统通路,从而使胃平滑肌收缩功能改变,增强DGP的胃排空功能。
Objective
On the basis of ancient literature, combined with today's clinical peculiarity of diabetes and complications of diabetes,probe into diabetes gastroparesis treatment for theoretical approach, and enrich Chinese medicine on diabetes stomach; Study the role of diabetes gastroparesis (DGP) rats gastric antral SCF-Kit pathway in the damage of interstitial cells of cajal (ICC) and the mechanism of TangWeiKang in order to lay the foundation to develop an effective medicine to control DGP.
Methods
Theoretical studies:Research the origin, the pathogenesis and treatment methods of gastric disease of diabetes, and discuss TangWeikang's prescription principles and efficacy analysis.
Experimental studies:At first,we have used Streptozotocin by cavitas abdominalis injection and high sugar high fat diet to irregularly feed (morning meal in odd-number days, afternoon eating in even-number days) rats to induce DGP model, and have divided rats into 7 Groups (normal comparison group, diabetes model group, diabetes gastroparesis model group,TangWeiKang high dose group, TangWeiKang medium dose group, TangWeiKang low dose group and XiShaBiLi treatment group) for experimental research. Then we have observed TangWeiKang'influence on improving carbohydrate and lipid metabolism and pancreaticβcell function of DGP model group rats; and observed each group of rats gastric antrum ICC ultrastructure through transmission electron microscopy; and taken the Western blot to detect gastric tissue c-kit and SCF protein expression level, and taken RT-PCR to determinate the expression of gastric tissue SCF mRNA.
Results
.1.Gastric disease of diabetes has a pathogenesis characteristic that Ben is deficient and Biao is excess. Furthermore, the spleen's deficiency is the most important,and the toxic'exuberance is the most obvious. Aiming at these, we have established a prescription TangWeiKang that can make the spleen-stomach healthy and smooth Qi and eliminate toxins.
2. In the research of making DM model and DGP model:Former 4 weeks after the model, quantities of food-intake of DM model group and DGP model group rats have obviously increased, compared with normal comparison group, and differences are significant (P<0.05 or P<0.01).Moreover, DM model group is more obvious. After 6 weeks, quantities of food-intake of DGP model group rats have decreased, compared with normal comparison group, and differences are significant in 8thweek(P<0.01). Former 2 weeks after the model, quantities of hydroposia of DM model group and DGP model group rats have obviously increased, compared with normal comparison group, and differences are significant (P<0.01). After 4 weeks, quantities of hydroposia of DGP model group rats have decreased more than that of DM model group.Besides, differences are more significant after 6 weeks, and are significant (P<0.05 or P<0.01). As an extension of time, the weights of DM model group and DGP model group rats have obviously reduced, compared with normal comparison group, and differences are signif icant(P<0.05 or P<0.01). Moreover, DGP model group is more obvious. and differences are significant (P<0.05 or P<0.01), compared with DM model group. At the same time, the stool of DM model group and DGP model group rats has appeared some changes, such as less, pale, softer, mutual adhesion, irregular shape and so on. Moreover, DGP model group is more obvious. The function of gastric emptying of DM model group and DGP model group rats has decreased, and the decline of gastric emptying of DM model group rats is non-obvious(P>0.05), compared with normal comparison group,but that of DGP model group rats is significant (P<0.01).
3. TangWeiKang' influence on improving carbohydrate and lipid metabolism and pancreaticβcell function of DGP model group rats: Fasting plasma glucose and fasting serum insulin and Homa-IR of TangWeiKang high dose group and medium dose group rats have obviously descended,but insulin sensitivity index of TangWeiKang high dose group and medium dose group rats have went up. Islet cell shape of TangWeiKang high dose group and medium dose group rats is more regular, and quantity of cell is more,and endochylema is more rich, compared with DGP model group rats. But the function of gastric emptying of TangWeiKang high dose group and medium dose group rats has no obvious difference with XiShaBiLi treatment group rats. These have explained TangWeiKang high dose and medium dose can improve IR by means of reducing glucose, and raise insulin sensibility,and renew pancreaticβcell function, and relieve clinical symptoms. There are obvious lipid accumulation in langerhans'islet in the DM model group and DGP model group rats, which can be important pathology factors that come into being DM and DGP. The weights of model group (DM model group and DGP model group)rats have dropped obviously in the experiment later stage, and DGP model group is most obvious. The reason can be high plasma glucose that lead to fat to resolve. The weights of TangWeiKang high dose group and medium dose group rats have obviously increased after invasion, and the ratio of fat in viscera and weight has obviously decreased,which have illustrated TangWeiKang can adjust lipid and put off the progress of DM.
4. TangWeiKang' influence on ICC of DGP model group rats:The gap joints between gastric antral ICC and smooth muscle and nerve endings have markedly decreased in the DGP model group rats through transmission electron microscopy, and the structures of intercellular connections are vague,and the gap has magnified. A part of ICC' basement layer has been separated with cytomembrane, which has formed cavity.we can also find mitochondria swelling, vacuolar degeneration,even dissolution, and cytoplasm resolving, and the quantity of cell organ has decreased. The gap joints between gastric antral ICC and smooth muscle and nerve endings are markedly more in the TangWeiKang high dose group and medium dose group than DGP model group after invasion, with more developed slide endoplasmic reticulum, Golgi apparatus and mitochondria. We have found the expression levels of c-kit protein of DGP model group have obviously decreased by western blot analysis method, compared with normal comparison group, and differences are significant (P<0.01). The expression levels of c-kit protein in the TangWeiKang high dose group and medium dose group are obviously higher than DGP model group after invasion (P<0.01), but the differences are non-obvious (P>0.05), compared with normal comparison group.
5. TangWeiKang'influence on SCF protein and gene expression of DGP model group rats:We have found the expression levels of SCF protein and gene expression of DGP model group have obviously decreased, compared with normal comparison group, and differences are significant (P<0.01). The expression levels of SCF protein and gene expression in the TangWeiKang high dose group and medium dose group are obviously higher than DGP model group after invasion (P<0.05 or P<0.01), but the differences are non-obvious (P>0.05), compared with normal comparison group.
Conclusion
1. Spleen-deficiency and losing in the transformation and transportation is a key link during diabetes mellitus formation. Toxins, such as toxic heat, damp toxin, ecchymosis toxin, turbid toxin and so on, are not only pathological products of diabetes mellitus,but also important pathogenic factors during gastric disease of diabetes formation. Gastric disease of diabetes have a pathogenesis characteristic that Ben is deficient and Biao is excess. Furthermore, the spleen's deficiency is the most importance, and the toxic'exuberance is the most obvious. Treatment principle should combine Bing with Zheng,and treat Biao and Ben at the same time. Aiming at these, we have established a prescription TangWeiKang that can make the spleen-stomach healthy and smooth Qi and eliminate toxins.
2. On the basis of single intraperitoneal injection STZ, we have fed model group rats on high sugar and high fat diet irregularly (morning meal in odd-number days, afternoon eating in even-number days).we have successfully copied diabetic gastroparesis model in this way.
3.TangWeiKang have a positive influence on improving carbohydrate and lipid metabolism and pancreaticβcell function, to a certain extent, can improve the IR, restore pancreatic isletβcell functions, enhance gastric emptying of DGP, and these are at the dose-effect relationship. TangWeiKang may rebuild the SCF-Kit pathway for ICC phenotype reversion by upregulating the level of SCF, so as to maintain normal gastrointestinal motor function.
引文
[1]Camilleri M. Advance in diabetic gastroparesis. Rev Gastroenterol Disorder,2002,25:912-917.
[2]田晗,吴汉妮.Cajal间质细胞与糖尿病胃轻瘫.国外医学内分泌学分册,2005,25(3)：200-202.
[3]Ward SM, Brennan MF, Jackson VM, et al. Role of PI3-kinase in the development of interstitial cells.and pacemaking in murine gastrointestinal smooth muscle. J Physiol,1999,516 (Pt 3): 835-846.
[4]Nakamura Y, Tajima F, Ishiga K, et al. Soluble c-kit receptor mobilizes hematopoietic stem cells to peripheral blood in mice. Exp Hematol,2004,32 (4):390-396.
[5]JelacicT, Linnekin D. PKC delta Plays opposite roles in growth mediated by wild-type Kit and an oncogenie Kit mutant. Blood, 2005,105(5):1923-1929.
[6]Lecuyer E, Herblot S, Saint-Denis M, et al.The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with SPI. Blood,2002,100(7):2430-2440.
[1]吴童.消渴病名考证疏义.福建中医学院学报,2007,17(2)：51-52.
[2]庄乾竹.古代消渴病学术史研究.中国中医科学院2003级博士论文,2006,10-11.
[3]赵昱,仝小林,刘素宾.中医治疗糖尿病临床研究的现状与思考[C].第十次全国中医糖尿病大会论文集,2007,396-399.
[4]郑红.试论脾失健运是消渴病发病的内在依据.湖北中医杂志,2009,31(2)：30-31.
[5]钟国隆.生理学[M].北京：人民卫生出版社,1993,3：115-116.
[6]丁学屏,沈稚舟,王耀萍,等.中西医结合糖尿病学[M].北京：人民卫生出版社,2004：95.
[7]郑红.中医治疗消渴病的组方配伍规律探讨[J].山东中医药大学学报,2008,32(4)：286.
[8]李运伦.毒邪的源流及其分类诠释[J].中医药学刊,2001,18(1)：44-45.
[9]王雪威,南红梅.南征教授从毒损肾络说论治消渴肾病经验.世界中西医结合杂志,2007,2(5)：254.
[10]陈蔚文.消化道药理与临床.北京：学苑出版社,2001.
[11]吴晓琰,陈蔚,俞茂华.黄芪多糖对糖尿病鼠胰岛IL-4、IFN-γ的影响.中国康复理论与实践,2008,14(2)：147-149.
[12]李伟,郑天珍,张英福,等.党参、枳实对大鼠胃肌条收缩活动的影响.中国中医基础医学杂志,2001,7(10)：31-33.
[13]郑天珍,李伟,田治峰,等.党参对动物在体胃运动的影响.兰州医学院学报,2000,26(4)：1-2.
[14]王君,邹原,贡德正.中药对胃肠运动的促进作用.大连医科大学学报,2001,23(1)：72-74.
[15]刘克敬,谢冬萍,李伟,等.陈皮、党参等中药对大鼠结肠肌条收缩活动的影响[J].山东大学学报(医学版),2003,41(1)：34-36.
[16]Takaaki Tai, Yaquhiko Akita,Kaoru Kinoshita, et al.Antemetic principles of poria cocos [J]. Planta Med,1995,61(6):527-530.
[17]左藤真友美,田井孝明.胰岛素作用增强活性组成物[P].日本公开特许公报,1998,10-330266.
[18]杨颖丽.枳实、青皮对平滑肌运动的影响.西北师范大学学报(自然科学版),2002,38(2)：114-117.
[19]郝庆,李岩,张恒军.柴胡枳实促胃肠动力作用机制的实验研究.辽宁药物与临床,2002,5(2)：65-66.
[20]郝庆,李岩.不同品种柴胡、枳实促胃肠动力作用及机制探讨.中国自然医学杂志,2002,4(3)：138-140.
[21]沈丕安.中药药理与临床运用.北京：人民卫生出版社,2006.
[22]张丽芬,赵进喜.中药鬼箭羽研究近况,中国中药杂志.2005,30(24)：1895-1898.
[23]刘颖,陆付耳,黄光英.丹参对HepG2细胞胰岛素抵抗状态的影响,医药导报.2008,27(3)：265-267.
[1]郭啸华,刘志红,李恒,等.高糖高脂饮食诱导的2型糖尿病大鼠模型及其肾病特点.中国糖尿病杂志,2002,10(5)：290-294.
[2]李晨钟,张素华,舒昌达,等.用高脂肪膳食复制胰岛素抵抗大鼠模型.基础医学与临床,2000,20(3)：93-95.
[3]Rackietan N, Raekietan ML, Nadkarni MR. Studies on diabetogenic action of streptozozin. Cancer Chemotherapy Reports,1993, 29:91-95.
[4]魏泓.医学实验动物学[M].成都：四川科学技术出版社,1997,347-349.
[5]李晨钟,张素华.胰岛素抵抗的动物模型.国外医学内分泌分册[J],1998,18：144-147.
[6]Storlien LH, Higgins JA, Thomas TC, et al.Diet composition and insulin action in animal models [J].Br J Nutr,2000,83 Suppl 1:S85-S90.
[7]王伯远,李坟松,黄高昇,等主编.病理学技术[M].北京：人民卫生出版社,2000,1：73.
[8]李光伟,潘孝仁,Lillioja S,等.检测人群胰岛素敏感性的一项新指数.中华内科杂志,1993,32：656-660.
[9]许曼音.糖尿病学[M].上海科学技术出版社,2003.
[10]Schvarcz E, Palmer M, Aman J, et al. Hypoglycaemia increases gastric emptying rate in patients with insulin-dependent diabetes mellitus. Diab Med,1993,10:660-663.
[11]Saksguchi T. Glucose signal in the nucleus of the vagus nerve modulates the cyclicity of gastric motility in rats. Brain Rea, 1994,641:163.
[12]Angel A. Hyperglycemia alters cytoplasmic Ca2+ influx in rat aortic smooth muscle cells. Am J Phsiol,1995,259:482.
[13]Xia P, Kramer RM, King GL. Identification of the mechanism for the inhibition of Na+-K+-adensosine triphosphatase by hyperglycemia involving-activation of protein kinase C and cytosolie phospho liase A2. J Clin Invest,1995,96(2):733-740.
[14]王雁,张彤彦,张建忠,等.西沙必利对糖尿病胃肠运动功能障碍的影响.基础医学与临床,1999,19(6)：516-521.
[15]Hasler WL, Soudah HC, Dulai G, et al. Mediation of hyperglycemia-evoked gastric slow-wave dysrhythmias by endogenous prostag-landins.Gastroenterology,1995,108 (3):727-736.
[16]李丽江,李雅江,张建华.普瑞博思对糖尿病胃肠道功能紊乱疗效的探讨.黑龙江医药科学,2000,23(1)：30-31.
[17]Rayner CK, Su YC, Doran SM, et al.The stimulation of antral motility by erythromycin is attenuated by hyperglycemia. Am J Gastroenterol,2000,95(9):2233-2241.
[18]Horowitz M,Frsaer R.Disorderded gastric motor function in diabetes mellitus. Diabetologia,1994,37:543-551.
[19]张锦.胰岛素抵抗与脂质代谢异常.辽宁医学杂志,1996,10(3)：118.
[20]罗丹,刘诗.糖尿病性胃轻瘫的胃动力异常机制.胃肠病学,2007,12(6)：373.
[21]Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA,2001,98(18):10344-10349.
[22]Ward SM, Brennan MF, Jackson VM, et al. Role of PI3-kinase in the development of interstitial cells and pacemaking in murine gastrointestinal smooth muscle. J Physiol,1999,516(Pt 3): 835-846.
[23]Nakamura Y, Tajima F, Ishiga K, et al. Soluble c-kit receptor mobilizes hematopoietic stem cells to peripheral blood in mice. Exp Hematol,2004,32(4):390-396.
[24]JelacicT, Linnekin D. PKC delta Plays opposite roles in growth mediated by wild-type Kit and an oncogenie Kit mutant. Blood, 2005,105(5):1923-1929.
[25]Lecuyer E, Herblot S, Saint-Denis M, et al.The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with SPI. Blood,2002,100(7):2430-2440.
[1]Ward SM, Sanders KM. Physiology and pathophysiology of the interstitial cell of Cajal:from bench to bedside. Ⅰ. Functional development and plasticity of interstitial cells of Cajal networks. Am J Physiol Gastrointest Liver Physiol,2001,281 (3): G602-G611.
[2]Komuro T, Seki K, Horiguchi K. Ultrastructural characterization of the interstitial cells of Cajal. Arch Histol Cytol 1999,62: 295-316.
[3]Torihashi S, Horisawa M, Watanabe Y. c-kit immunoreactive interstitial cells in the human gastrointestinal tract. J Autonomic Nerv Syst,1999,75:38-50.
[4]identification of the c-kit-expressing interstitial cells in the rat stomach:a comparision of control and Ws/Ws mutant rats. Cell Tissue Res,1997,289:137-143.
[5]Torihashi S, Nishi K, Tokutomi Y, et al. Blockade of kit signaling induces trans differentiation of interstitial cells of Cajal to a smooth muscle phenotype. Gastroenterology,1999,117: 140-148.
[6]Edwards FR, Hirst GD. An electrical analysis of slow wave propagation in the guinea-pig gastric antrum. J Physiol,2006, 571 (Pt1):179-189.
[7]Hudson NP, Mayhew IG, Pearson GT. Interstitial cells of Cajal and electrical activity of smooth muscle in porcine ileum. Acta Physiol(Oxf),2006,187(3):391-397.
[8]Ward SM, Sanders KM, Hirst GD. Role of interstitial cells of Cajal in neural control of gastrointestinal smooth muscles. Neurogastroenterol Motil,2004,16 Suppl 1:112-117.
[9]Ward SM, McLaren GJ, Sanders KM. Interstitial cells of Cajal in the deep muscular plexus mediate enteric motor neurotransmission in the mouse small intestine. J Physiol, 2006,573(Pt 1):147-159.
[10]孙金山,王宝西.Cajal间质细胞与胃肠动力疾病[J].中国当代儿 科杂志,2006,8(2)：164-168.
[11]李毅,齐清会.胃肠道神经-Cajal间质细胞-平滑肌网络研究进展[J].国际消化病杂志,2007,27(3)：225-227.
[12]陈慧群.消化道Cajal间质细胞及其受体的研究进展.胃肠病学和肝病学杂志,2008,17(4)：332-334.
[13]Orellana JA, Palacios-Prado N, S a ez JC. Chlorpromazine reduces the intercellular communication via gap junctions in mammalian cells[J]. Toxicol Appl Pharmacol,2006,213(3):187-197.
[14]Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA,2001,98(18):10344-10349.
[15]Rich A, Miller SM, Gibbons SJ, et al. Local presentation of steel factor increases expression of c-kit immunoreactive interstitial cells of Cajal in culture. Am J Physiol Gastrointest Liver Physiol,2003,284(2):G313-G320.
[16]Ward SM,Ordog T,Bayguinov JR,et al. Development of interstitial cells of Cajal and pacemaking in mice lacking enteric nerves. Gastroenterology,1999,117(3):584-594.
[17]Ward SM, Brennan MF, Jackson VM, et al. Role of PI3-kinase in the development of interstitial cells and pacemaking in murine gastrointestinal smooth muscle. J Physiol,1999,516 (Pt 3): 835-846.
[18]Ward SM, Burns AJ, Torihashi S, et al. Impaired development of interstitial cells and intestinal electrical rhythmicity in steel mutants. Am J Physiol,1995,269(6 Pt 1):C1577-C1585.
[19]Mikkelsen HB, Malysz J, Huizinga JD, et al. Action Potential generation, Kit receptor immunohistochemistry and morphology of steel-Diekie(S1/S1d) mutant mouse small intestine. Neurogastroenterol Motil,1998,10:11-26.
[20]Torihashi S, Nishi K, Tokutomi Y, et al. Blockade of kit signaling induces transdifferentiation of interstitial cells of cajal to a smooth muscle phenotype. Gastroenterology,1999,117(1): 140-148.
[21]Ordog T, Ward SM, Sanders KM. Interstitial cells of Cajal generate Electrical slow waves in the murine stomach. J Physiol Lond,1999,518:257-269.
[22]龙庆林,房殿春,史洪涛,等.糖尿病大鼠胃窦SCF-Kit信号改变及其对Cajal间质细胞的影响.第三军医大学学报,2007,29(2)：141-143.
[23]罗云,林琳,张红杰,等.糖尿病慢传输运动结肠Cajal间质细胞和干细胞因子的变化.世界华人消化杂志,2007,15(5)：458-463.
[24]Horv a thVJ, Vittal H, Lorincz A, et al. Reduced stem cell factor links smooth myopathy and loss of interstitial cells of cajal in murine diabetic gastroparesis. Gastroenterology,2006, 130(3):759-770.
[25]龙庆林,房殿春,史洪涛,等.糖尿病大鼠胃Cajal间质细胞超微结构的改变.中华消化杂志,2004,24(7)：434-435.
[26]Ordog T, Takayama I, Cheung WK, et al. Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis. Diabetes,2000,49(10):1731-1739.
[27]Iwasaki H, Kajimura M, Osawa S, et al. A deficiency of gastric interstitial cells of Cajal accompanied by decreased expression of neuronal nitric oxide synthase and substance P in patients with type 2 diabetes mellitus. J Gastroenterol, 2006,41(11):1076-1087.
[1]白煜,白宇宁.对糖尿病性胃轻瘫中医病机与辨证思路的探讨.第八 届全国中医糖尿病学术大会论文汇编,170-172.
[2]梁幼雅.糖尿病胃轻瘫的病机特点及辨证治疗.浙江中医杂志,2004,(8)：330-331.
[3]刘志勤,吕蕾.辨证论治糖尿病性胃轻瘫24例.河北中医,2003,25(10)：738-739.
[4]刘桠,康健,杜英杰.糖尿病胃轻瘫的病因病机及证治研究进展.光明中医,2007,22(4)：70-72.
[5]曾娟,张荣华,魏春山,等.从痰瘀入手治疗糖尿病胃轻瘫机理探讨.时珍国医国药,2007,18(3)：723-724.
[6]王新歧.赵进喜治疗糖尿病性胃轻瘫经验.浙江中医杂志,2005,7：280-281.
[7]崔雅忠.糖尿病胃轻瘫与消渴兼证“痞证”及其中医治疗.中国临床医生,2006,34(5)：20-21.
[8]周萌.从痞满论治糖尿病胃轻瘫的思路.河南中医,2008,28(3)：15-16.
[9]高志扬.糖尿病性胃轻瘫辨治心法[J].四川中医,2003,21(8)：18-19.
[10]曾娟,张荣华,魏春山,等.从痰瘀入手治疗糖尿病胃轻瘫机理探讨.时珍国医国药,2007,18(3)：723-724.
[11]付旭彦.半夏泻心汤加减治疗糖尿病胃轻瘫83例临床观察[J].中国现代医药杂志,2006,8(6)：20.
[12]方军,陈式祥.半夏泻心汤加减治疗胃轻瘫综合征42例[J].实用中医药杂志,2005,21(2)：76-77.
[13]邱英明,单敬文,胡天赤.半夏泻心汤加味治疗糖尿病胃轻瘫35例[J].福建中医药,2004,35(5)：25.
[14]王卫平.香砂六君子汤加减治疗糖尿病胃轻瘫疗效观察[J].基层医学论坛,2004,8(2)：114.
[15]邱伟中,刘和强.四磨汤口服液治疗糖尿病胃轻瘫疗效观察[J].现 代医院,2005,5(1)：35-36.
[16]章其春,张自正.藿香正气软胶囊治疗糖尿病胃轻瘫30例[J].浙江中西医结合杂志,2004,14(9):571.
[17]蔡文.血府逐瘀汤加味治疗糖尿病性胃轻瘫82例[J].江西中医药,2004,35(3)：27.
[18]蔡锦莲,黄彦敏.疏肝和胃法治疗糖尿病胃轻瘫临床观察[J].中医药学刊,2006,24(5)：847.
[19]袁瞳.半夏厚朴汤加减治疗胃轻瘫综合征38例[J].山东中医药杂志,2006,25(7)：450-451.
[20]梁贵廷.加味香苏散治疗糖尿病胃轻瘫98例[J].中医杂志,2003,44(3)：209.
[21]鲁海婷.温胆汤加减治疗糖尿病性胃轻瘫42例[J].湖北中医杂志,2003,23(2)：10.
[22]方家选.补中益气汤加味治疗糖尿病性胃轻瘫64例[J].陕西中医,2007,28(1)：43-44.
[23]黄红勤.丹参饮合二陈汤治疗糖尿病胃轻瘫40例[J].新中医,2007,39(1)：68.
[24]张庆伟.小柴胡汤加味治疗2型糖尿病胃轻瘫96例[J].中医杂志,2007,48(7)：585.
[25]曾艺鹏,王爱华,胡蕴刚.复方配伍治疗伴湿热兼证糖尿病性胃轻瘫的研究[J].现代中西医结合杂志,2006,15(5)：2023-2024.
[26]周红,钟灵,钟毅.胃肠舒治疗糖尿病胃轻瘫48例临床研究[J].中医杂志,2006,47(5)：352-354.
[27]陆新.中西医结合治疗糖尿病性胃轻瘫60例临床观察.江苏中医药,2005,26(9)：17-18.
[28]刘勇会,林亚萍,宋凤婷.疏肝消痞汤治疗糖尿病胃轻瘫41例临床观察[J].河北中医,2006,28(12)：900-901.
[29]包扬.姜喆教授治疗糖尿病胃轻瘫经验撷菁.吉林中医药,2006, 26(3)：78.
[30]孙维峰,孙桂华,等.糖尿病胃轻瘫中医证型与胃动力改变关系的研究.安徽中医学院学报,2003,22(2)：17-19.
[31]梁幼雅,朗建英,等.糖尿病胃轻瘫中医证候特点及其证候与胃排空障碍的关系.上海中医药杂志,2004,38(8)：3-5.
[32]孙泽庭,吴芝炯,隋艳华.’四氧嘧啶和熟地黄诱导糖尿病胃轻瘫大鼠模型初探[J].中国中医基础医学杂志,2003,9(1)：37-38.
[33]肖万泽,陈俊,等.糖胃康对糖尿病胃轻瘫大鼠胃肠推进作用的实验研究.辽宁中医杂志,2003,30(9)：773-774.
[34]曲竹秋,穆标,等.健脾理气法治疗糖尿病胃轻瘫的研究.第八届全国中医糖尿病学术大会论文汇编,307-310.
[35]钱秋海,王志超,等.糖胃安对糖尿病胃轻瘫模型大鼠超微结构的影响.中国临床药理学杂志,2007,23(4)：311-312.
[36]钟毅,赵志明,等.胃肠舒和血流干预药物对实验性糖尿病胃轻瘫大鼠的影响.辽宁中医药大学学报,2008,10(5)：165-169.
[37]李丽霞,林国华.电针对糖尿病胃轻瘫大鼠MTL、GAS的影响.河南中医学院学报,2006,5(3)：25-27.
[2]田晗,吴汉妮.Cajal间质细胞与糖尿病胃轻瘫.国外医学内分泌学分册,2005,25(3)：200-202.
[3]Ward SM, Brennan MF, Jackson VM, et al. Role of PI3-kinase in the development of interstitial cells.and pacemaking in murine gastrointestinal smooth muscle. J Physiol,1999,516 (Pt 3): 835-846.
[4]Nakamura Y, Tajima F, Ishiga K, et al. Soluble c-kit receptor mobilizes hematopoietic stem cells to peripheral blood in mice. Exp Hematol,2004,32 (4):390-396.
[5]JelacicT, Linnekin D. PKC delta Plays opposite roles in growth mediated by wild-type Kit and an oncogenie Kit mutant. Blood, 2005,105(5):1923-1929.
[6]Lecuyer E, Herblot S, Saint-Denis M, et al.The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with SPI. Blood,2002,100(7):2430-2440.
[1]吴童.消渴病名考证疏义.福建中医学院学报,2007,17(2)：51-52.
[2]庄乾竹.古代消渴病学术史研究.中国中医科学院2003级博士论文,2006,10-11.
[3]赵昱,仝小林,刘素宾.中医治疗糖尿病临床研究的现状与思考[C].第十次全国中医糖尿病大会论文集,2007,396-399.
[4]郑红.试论脾失健运是消渴病发病的内在依据.湖北中医杂志,2009,31(2)：30-31.
[5]钟国隆.生理学[M].北京：人民卫生出版社,1993,3：115-116.
[6]丁学屏,沈稚舟,王耀萍,等.中西医结合糖尿病学[M].北京：人民卫生出版社,2004：95.
[7]郑红.中医治疗消渴病的组方配伍规律探讨[J].山东中医药大学学报,2008,32(4)：286.
[8]李运伦.毒邪的源流及其分类诠释[J].中医药学刊,2001,18(1)：44-45.
[9]王雪威,南红梅.南征教授从毒损肾络说论治消渴肾病经验.世界中西医结合杂志,2007,2(5)：254.
[10]陈蔚文.消化道药理与临床.北京：学苑出版社,2001.
[11]吴晓琰,陈蔚,俞茂华.黄芪多糖对糖尿病鼠胰岛IL-4、IFN-γ的影响.中国康复理论与实践,2008,14(2)：147-149.
[12]李伟,郑天珍,张英福,等.党参、枳实对大鼠胃肌条收缩活动的影响.中国中医基础医学杂志,2001,7(10)：31-33.
[13]郑天珍,李伟,田治峰,等.党参对动物在体胃运动的影响.兰州医学院学报,2000,26(4)：1-2.
[14]王君,邹原,贡德正.中药对胃肠运动的促进作用.大连医科大学学报,2001,23(1)：72-74.
[15]刘克敬,谢冬萍,李伟,等.陈皮、党参等中药对大鼠结肠肌条收缩活动的影响[J].山东大学学报(医学版),2003,41(1)：34-36.
[16]Takaaki Tai, Yaquhiko Akita,Kaoru Kinoshita, et al.Antemetic principles of poria cocos [J]. Planta Med,1995,61(6):527-530.
[17]左藤真友美,田井孝明.胰岛素作用增强活性组成物[P].日本公开特许公报,1998,10-330266.
[18]杨颖丽.枳实、青皮对平滑肌运动的影响.西北师范大学学报(自然科学版),2002,38(2)：114-117.
[19]郝庆,李岩,张恒军.柴胡枳实促胃肠动力作用机制的实验研究.辽宁药物与临床,2002,5(2)：65-66.
[20]郝庆,李岩.不同品种柴胡、枳实促胃肠动力作用及机制探讨.中国自然医学杂志,2002,4(3)：138-140.
[21]沈丕安.中药药理与临床运用.北京：人民卫生出版社,2006.
[22]张丽芬,赵进喜.中药鬼箭羽研究近况,中国中药杂志.2005,30(24)：1895-1898.
[23]刘颖,陆付耳,黄光英.丹参对HepG2细胞胰岛素抵抗状态的影响,医药导报.2008,27(3)：265-267.
[1]郭啸华,刘志红,李恒,等.高糖高脂饮食诱导的2型糖尿病大鼠模型及其肾病特点.中国糖尿病杂志,2002,10(5)：290-294.
[2]李晨钟,张素华,舒昌达,等.用高脂肪膳食复制胰岛素抵抗大鼠模型.基础医学与临床,2000,20(3)：93-95.
[3]Rackietan N, Raekietan ML, Nadkarni MR. Studies on diabetogenic action of streptozozin. Cancer Chemotherapy Reports,1993, 29:91-95.
[4]魏泓.医学实验动物学[M].成都：四川科学技术出版社,1997,347-349.
[5]李晨钟,张素华.胰岛素抵抗的动物模型.国外医学内分泌分册[J],1998,18：144-147.
[6]Storlien LH, Higgins JA, Thomas TC, et al.Diet composition and insulin action in animal models [J].Br J Nutr,2000,83 Suppl 1:S85-S90.
[7]王伯远,李坟松,黄高昇,等主编.病理学技术[M].北京：人民卫生出版社,2000,1：73.
[8]李光伟,潘孝仁,Lillioja S,等.检测人群胰岛素敏感性的一项新指数.中华内科杂志,1993,32：656-660.
[9]许曼音.糖尿病学[M].上海科学技术出版社,2003.
[10]Schvarcz E, Palmer M, Aman J, et al. Hypoglycaemia increases gastric emptying rate in patients with insulin-dependent diabetes mellitus. Diab Med,1993,10:660-663.
[11]Saksguchi T. Glucose signal in the nucleus of the vagus nerve modulates the cyclicity of gastric motility in rats. Brain Rea, 1994,641:163.
[12]Angel A. Hyperglycemia alters cytoplasmic Ca2+ influx in rat aortic smooth muscle cells. Am J Phsiol,1995,259:482.
[13]Xia P, Kramer RM, King GL. Identification of the mechanism for the inhibition of Na+-K+-adensosine triphosphatase by hyperglycemia involving-activation of protein kinase C and cytosolie phospho liase A2. J Clin Invest,1995,96(2):733-740.
[14]王雁,张彤彦,张建忠,等.西沙必利对糖尿病胃肠运动功能障碍的影响.基础医学与临床,1999,19(6)：516-521.
[15]Hasler WL, Soudah HC, Dulai G, et al. Mediation of hyperglycemia-evoked gastric slow-wave dysrhythmias by endogenous prostag-landins.Gastroenterology,1995,108 (3):727-736.
[16]李丽江,李雅江,张建华.普瑞博思对糖尿病胃肠道功能紊乱疗效的探讨.黑龙江医药科学,2000,23(1)：30-31.
[17]Rayner CK, Su YC, Doran SM, et al.The stimulation of antral motility by erythromycin is attenuated by hyperglycemia. Am J Gastroenterol,2000,95(9):2233-2241.
[18]Horowitz M,Frsaer R.Disorderded gastric motor function in diabetes mellitus. Diabetologia,1994,37:543-551.
[19]张锦.胰岛素抵抗与脂质代谢异常.辽宁医学杂志,1996,10(3)：118.
[20]罗丹,刘诗.糖尿病性胃轻瘫的胃动力异常机制.胃肠病学,2007,12(6)：373.
[21]Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA,2001,98(18):10344-10349.
[22]Ward SM, Brennan MF, Jackson VM, et al. Role of PI3-kinase in the development of interstitial cells and pacemaking in murine gastrointestinal smooth muscle. J Physiol,1999,516(Pt 3): 835-846.
[23]Nakamura Y, Tajima F, Ishiga K, et al. Soluble c-kit receptor mobilizes hematopoietic stem cells to peripheral blood in mice. Exp Hematol,2004,32(4):390-396.
[24]JelacicT, Linnekin D. PKC delta Plays opposite roles in growth mediated by wild-type Kit and an oncogenie Kit mutant. Blood, 2005,105(5):1923-1929.
[25]Lecuyer E, Herblot S, Saint-Denis M, et al.The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with SPI. Blood,2002,100(7):2430-2440.
[1]Ward SM, Sanders KM. Physiology and pathophysiology of the interstitial cell of Cajal:from bench to bedside. Ⅰ. Functional development and plasticity of interstitial cells of Cajal networks. Am J Physiol Gastrointest Liver Physiol,2001,281 (3): G602-G611.
[2]Komuro T, Seki K, Horiguchi K. Ultrastructural characterization of the interstitial cells of Cajal. Arch Histol Cytol 1999,62: 295-316.
[3]Torihashi S, Horisawa M, Watanabe Y. c-kit immunoreactive interstitial cells in the human gastrointestinal tract. J Autonomic Nerv Syst,1999,75:38-50.
[4]identification of the c-kit-expressing interstitial cells in the rat stomach:a comparision of control and Ws/Ws mutant rats. Cell Tissue Res,1997,289:137-143.
[5]Torihashi S, Nishi K, Tokutomi Y, et al. Blockade of kit signaling induces trans differentiation of interstitial cells of Cajal to a smooth muscle phenotype. Gastroenterology,1999,117: 140-148.
[6]Edwards FR, Hirst GD. An electrical analysis of slow wave propagation in the guinea-pig gastric antrum. J Physiol,2006, 571 (Pt1):179-189.
[7]Hudson NP, Mayhew IG, Pearson GT. Interstitial cells of Cajal and electrical activity of smooth muscle in porcine ileum. Acta Physiol(Oxf),2006,187(3):391-397.
[8]Ward SM, Sanders KM, Hirst GD. Role of interstitial cells of Cajal in neural control of gastrointestinal smooth muscles. Neurogastroenterol Motil,2004,16 Suppl 1:112-117.
[9]Ward SM, McLaren GJ, Sanders KM. Interstitial cells of Cajal in the deep muscular plexus mediate enteric motor neurotransmission in the mouse small intestine. J Physiol, 2006,573(Pt 1):147-159.
[10]孙金山,王宝西.Cajal间质细胞与胃肠动力疾病[J].中国当代儿 科杂志,2006,8(2)：164-168.
[11]李毅,齐清会.胃肠道神经-Cajal间质细胞-平滑肌网络研究进展[J].国际消化病杂志,2007,27(3)：225-227.
[12]陈慧群.消化道Cajal间质细胞及其受体的研究进展.胃肠病学和肝病学杂志,2008,17(4)：332-334.
[13]Orellana JA, Palacios-Prado N, S a ez JC. Chlorpromazine reduces the intercellular communication via gap junctions in mammalian cells[J]. Toxicol Appl Pharmacol,2006,213(3):187-197.
[14]Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA,2001,98(18):10344-10349.
[15]Rich A, Miller SM, Gibbons SJ, et al. Local presentation of steel factor increases expression of c-kit immunoreactive interstitial cells of Cajal in culture. Am J Physiol Gastrointest Liver Physiol,2003,284(2):G313-G320.
[16]Ward SM,Ordog T,Bayguinov JR,et al. Development of interstitial cells of Cajal and pacemaking in mice lacking enteric nerves. Gastroenterology,1999,117(3):584-594.
[17]Ward SM, Brennan MF, Jackson VM, et al. Role of PI3-kinase in the development of interstitial cells and pacemaking in murine gastrointestinal smooth muscle. J Physiol,1999,516 (Pt 3): 835-846.
[18]Ward SM, Burns AJ, Torihashi S, et al. Impaired development of interstitial cells and intestinal electrical rhythmicity in steel mutants. Am J Physiol,1995,269(6 Pt 1):C1577-C1585.
[19]Mikkelsen HB, Malysz J, Huizinga JD, et al. Action Potential generation, Kit receptor immunohistochemistry and morphology of steel-Diekie(S1/S1d) mutant mouse small intestine. Neurogastroenterol Motil,1998,10:11-26.
[20]Torihashi S, Nishi K, Tokutomi Y, et al. Blockade of kit signaling induces transdifferentiation of interstitial cells of cajal to a smooth muscle phenotype. Gastroenterology,1999,117(1): 140-148.
[21]Ordog T, Ward SM, Sanders KM. Interstitial cells of Cajal generate Electrical slow waves in the murine stomach. J Physiol Lond,1999,518:257-269.
[22]龙庆林,房殿春,史洪涛,等.糖尿病大鼠胃窦SCF-Kit信号改变及其对Cajal间质细胞的影响.第三军医大学学报,2007,29(2)：141-143.
[23]罗云,林琳,张红杰,等.糖尿病慢传输运动结肠Cajal间质细胞和干细胞因子的变化.世界华人消化杂志,2007,15(5)：458-463.
[24]Horv a thVJ, Vittal H, Lorincz A, et al. Reduced stem cell factor links smooth myopathy and loss of interstitial cells of cajal in murine diabetic gastroparesis. Gastroenterology,2006, 130(3):759-770.
[25]龙庆林,房殿春,史洪涛,等.糖尿病大鼠胃Cajal间质细胞超微结构的改变.中华消化杂志,2004,24(7)：434-435.
[26]Ordog T, Takayama I, Cheung WK, et al. Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis. Diabetes,2000,49(10):1731-1739.
[27]Iwasaki H, Kajimura M, Osawa S, et al. A deficiency of gastric interstitial cells of Cajal accompanied by decreased expression of neuronal nitric oxide synthase and substance P in patients with type 2 diabetes mellitus. J Gastroenterol, 2006,41(11):1076-1087.
[1]白煜,白宇宁.对糖尿病性胃轻瘫中医病机与辨证思路的探讨.第八 届全国中医糖尿病学术大会论文汇编,170-172.
[2]梁幼雅.糖尿病胃轻瘫的病机特点及辨证治疗.浙江中医杂志,2004,(8)：330-331.
[3]刘志勤,吕蕾.辨证论治糖尿病性胃轻瘫24例.河北中医,2003,25(10)：738-739.
[4]刘桠,康健,杜英杰.糖尿病胃轻瘫的病因病机及证治研究进展.光明中医,2007,22(4)：70-72.
[5]曾娟,张荣华,魏春山,等.从痰瘀入手治疗糖尿病胃轻瘫机理探讨.时珍国医国药,2007,18(3)：723-724.
[6]王新歧.赵进喜治疗糖尿病性胃轻瘫经验.浙江中医杂志,2005,7：280-281.
[7]崔雅忠.糖尿病胃轻瘫与消渴兼证“痞证”及其中医治疗.中国临床医生,2006,34(5)：20-21.
[8]周萌.从痞满论治糖尿病胃轻瘫的思路.河南中医,2008,28(3)：15-16.
[9]高志扬.糖尿病性胃轻瘫辨治心法[J].四川中医,2003,21(8)：18-19.
[10]曾娟,张荣华,魏春山,等.从痰瘀入手治疗糖尿病胃轻瘫机理探讨.时珍国医国药,2007,18(3)：723-724.
[11]付旭彦.半夏泻心汤加减治疗糖尿病胃轻瘫83例临床观察[J].中国现代医药杂志,2006,8(6)：20.
[12]方军,陈式祥.半夏泻心汤加减治疗胃轻瘫综合征42例[J].实用中医药杂志,2005,21(2)：76-77.
[13]邱英明,单敬文,胡天赤.半夏泻心汤加味治疗糖尿病胃轻瘫35例[J].福建中医药,2004,35(5)：25.
[14]王卫平.香砂六君子汤加减治疗糖尿病胃轻瘫疗效观察[J].基层医学论坛,2004,8(2)：114.
[15]邱伟中,刘和强.四磨汤口服液治疗糖尿病胃轻瘫疗效观察[J].现 代医院,2005,5(1)：35-36.
[16]章其春,张自正.藿香正气软胶囊治疗糖尿病胃轻瘫30例[J].浙江中西医结合杂志,2004,14(9):571.
[17]蔡文.血府逐瘀汤加味治疗糖尿病性胃轻瘫82例[J].江西中医药,2004,35(3)：27.
[18]蔡锦莲,黄彦敏.疏肝和胃法治疗糖尿病胃轻瘫临床观察[J].中医药学刊,2006,24(5)：847.
[19]袁瞳.半夏厚朴汤加减治疗胃轻瘫综合征38例[J].山东中医药杂志,2006,25(7)：450-451.
[20]梁贵廷.加味香苏散治疗糖尿病胃轻瘫98例[J].中医杂志,2003,44(3)：209.
[21]鲁海婷.温胆汤加减治疗糖尿病性胃轻瘫42例[J].湖北中医杂志,2003,23(2)：10.
[22]方家选.补中益气汤加味治疗糖尿病性胃轻瘫64例[J].陕西中医,2007,28(1)：43-44.
[23]黄红勤.丹参饮合二陈汤治疗糖尿病胃轻瘫40例[J].新中医,2007,39(1)：68.
[24]张庆伟.小柴胡汤加味治疗2型糖尿病胃轻瘫96例[J].中医杂志,2007,48(7)：585.
[25]曾艺鹏,王爱华,胡蕴刚.复方配伍治疗伴湿热兼证糖尿病性胃轻瘫的研究[J].现代中西医结合杂志,2006,15(5)：2023-2024.
[26]周红,钟灵,钟毅.胃肠舒治疗糖尿病胃轻瘫48例临床研究[J].中医杂志,2006,47(5)：352-354.
[27]陆新.中西医结合治疗糖尿病性胃轻瘫60例临床观察.江苏中医药,2005,26(9)：17-18.
[28]刘勇会,林亚萍,宋凤婷.疏肝消痞汤治疗糖尿病胃轻瘫41例临床观察[J].河北中医,2006,28(12)：900-901.
[29]包扬.姜喆教授治疗糖尿病胃轻瘫经验撷菁.吉林中医药,2006, 26(3)：78.
[30]孙维峰,孙桂华,等.糖尿病胃轻瘫中医证型与胃动力改变关系的研究.安徽中医学院学报,2003,22(2)：17-19.
[31]梁幼雅,朗建英,等.糖尿病胃轻瘫中医证候特点及其证候与胃排空障碍的关系.上海中医药杂志,2004,38(8)：3-5.
[32]孙泽庭,吴芝炯,隋艳华.’四氧嘧啶和熟地黄诱导糖尿病胃轻瘫大鼠模型初探[J].中国中医基础医学杂志,2003,9(1)：37-38.
[33]肖万泽,陈俊,等.糖胃康对糖尿病胃轻瘫大鼠胃肠推进作用的实验研究.辽宁中医杂志,2003,30(9)：773-774.
[34]曲竹秋,穆标,等.健脾理气法治疗糖尿病胃轻瘫的研究.第八届全国中医糖尿病学术大会论文汇编,307-310.
[35]钱秋海,王志超,等.糖胃安对糖尿病胃轻瘫模型大鼠超微结构的影响.中国临床药理学杂志,2007,23(4)：311-312.
[36]钟毅,赵志明,等.胃肠舒和血流干预药物对实验性糖尿病胃轻瘫大鼠的影响.辽宁中医药大学学报,2008,10(5)：165-169.
[37]李丽霞,林国华.电针对糖尿病胃轻瘫大鼠MTL、GAS的影响.河南中医学院学报,2006,5(3)：25-27.